{"id":"ocriplasmin-125-g","safety":{"commonSideEffects":[{"rate":null,"effect":"Retinal detachment"},{"rate":null,"effect":"Retinal tear"},{"rate":null,"effect":"Photopsia (flashing lights)"},{"rate":null,"effect":"Floaters"},{"rate":null,"effect":"Conjunctival hemorrhage"}]},"_chembl":{"chemblId":"CHEMBL2095222","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ocriplasmin is a truncated form of human plasmin that selectively degrades extracellular matrix proteins at the vitreoretinal interface. By breaking down the protein scaffold that anchors the vitreous to the retina, it facilitates posterior vitreous detachment and relieves tractional forces that contribute to macular pathology. This mechanism allows non-surgical resolution of vitreoretinal adhesions in conditions like vitreomacular traction and macular holes.","oneSentence":"Ocriplasmin is a recombinant microplasmin that enzymatically cleaves fibronectin and laminin in the vitreous to dissolve vitreous-retinal adhesions.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:23:51.044Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vitreomacular traction syndrome"},{"name":"Symptomatic diabetic macular edema with vitreous traction"},{"name":"Myopic traction maculopathy"}]},"trialDetails":[{"nctId":"NCT01287988","phase":"","title":"Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2011-05","conditions":"Symptomatic Vitreomacular Adhesion","enrollment":24},{"nctId":"NCT00435539","phase":"PHASE2","title":"A Study to Compare Multiple Doses Intravitreal Microplasmin for Treatment of Patients With Vitreomacular Traction (MIVI-IIt)","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2007-02","conditions":"Vitreomacular Traction","enrollment":60},{"nctId":"NCT00798317","phase":"PHASE3","title":"Trial of Microplasmin Intravitreal Injection for Non-Surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-007) Trial.","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2008-12","conditions":"Vitreomacular Adhesion","enrollment":326},{"nctId":"NCT00412958","phase":"PHASE2","title":"A Study of the Safety and Efficacy of Microplasmin to Induce a Posterior Vitreous Detachment (MIVI III)","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2006-12","conditions":"Vitrectomy","enrollment":125},{"nctId":"NCT00781859","phase":"PHASE3","title":"Trial of Microplasmin Intravitreal Injection for Non-surgical Treatment of Focal Vitreomacular Adhesion. The MIVI-TRUST (TG-MV-006) Trial.","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2008-12","conditions":"Vitreomacular Adhesion","enrollment":326},{"nctId":"NCT00412451","phase":"PHASE2","title":"A Multicenter Study to Compare Multiple Doses of Intravitreal Microplasmin Versus Sham Injection for Treatment of Patients With Diabetic Macular Edema (DME)","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2006-12","conditions":"Diabetic Macular Edema","enrollment":51},{"nctId":"NCT01159665","phase":"PHASE2","title":"The Purpose of This Study is to Evaluate the Pharmacokinetic Properties of Intravitreal Ocriplasmin Prior to Planned Primary Pars Plana Vitrectomy (PPV)","status":"COMPLETED","sponsor":"ThromboGenics","startDate":"2010-07","conditions":"Vitrectomy","enrollment":38}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Microplasmin"],"phase":"phase_3","status":"active","brandName":"Ocriplasmin 125µg","genericName":"Ocriplasmin 125µg","companyName":"ThromboGenics","companyId":"thrombogenics","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Ocriplasmin is a recombinant microplasmin that enzymatically cleaves fibronectin and laminin in the vitreous to dissolve vitreous-retinal adhesions. Used for Vitreomacular traction syndrome, Symptomatic diabetic macular edema with vitreous traction, Myopic traction maculopathy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}